Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
Globe Newswire•22/09/2026•07:05 ET
1
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –
– Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses –
Get started
Create a free account to read the full story and Whiz Insights.